Article
Pediatrics
Mikhail M. Kostik, Ekaterina V. Gaidar, Lubov S. Sorokina, Ilya S. Avrusin, Tatiana N. Nikitina, Eugenia A. Isupova, Irina A. Chikova, Yuri Yu. Korin, Elizaveta D. Orlova, Ludmila S. Snegireva, Vera V. Masalova, Margarita F. Dubko, Olga V. Kalashnikova, Vyacheslav G. Chasnyk
Summary: The presence of uveitis is a risk factor for JIA flare, while methotrexate can reduce the cumulative flare probability.
FRONTIERS IN PEDIATRICS
(2022)
Review
Medicine, General & Internal
Pierre Quartier
Summary: Children with early onset juvenile idiopathic arthritis, especially with positive antinuclear antibodies, may develop chronic anterior uveitis, which requires regular slit lamp examination and prompt treatment. Therapy options range from local steroid treatment to systemic immunomodulatory therapy, tailored to individual patient needs, with involvement of expert ophthalmologists and pediatricians. Treatment should not be easily interrupted and may need to be intensified in certain cases for optimal disease control.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Ophthalmology
Sanna Leinonen
Summary: This perspective aimed to explore the screening of uveitis in Nordic children with JIA, summarizing the predictors and recommendations for JIA-uveitis screening. Younger age, positive antinuclear antibody titre, specific subtypes of JIA, and shorter duration of JIA are predictors of uveitis in JIA. Methotrexate and monoclonal TNF inhibitor treatment can reduce the risk of JIA-uveitis. Guidelines for screening intervals and length were prepared based on known risk factors and the Nordic population.
ACTA OPHTHALMOLOGICA
(2023)
Article
Ophthalmology
Francesca Tirelli, Maria Elisabetta Zannin, Fabio Vittadello, Jacopo Agnolucci, Monica Mazzarolo, Francesco Zulian
Summary: The study evaluated the long-term efficacy of MTX monotherapy in patients with JIA-U and found that although effective in the early stages, MTX showed poor disease control in the long term, with many patients eventually needing biologic agents for treatment.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2022)
Review
Pediatrics
Emil Carlsson, Michael W. Beresford, Athimalaipet Ramanan, Andrew D. Dick, Christian M. Hedrich
Summary: Early treatment and frequent screening are crucial for controlling JIA-associated uveitis, which poses a significant risk for serious complications. The identification of specific risk factors for JIA-associated uveitis is a key focus of research as our understanding of pathogenic drivers is still incomplete. Genomic, transcriptomic, and proteomic factors have been identified as potential risk factors, and therapeutic strategies are being discussed.
Article
Ophthalmology
Raphaelle Ores, Celine Terrada, Marie-Helene Errera, Jennifer E. Thorne, Raphael Doukhan, Nathalie Cassoux, Benjamin Penaud, Phuc LeHoang, Pierre Marie Quartier, Bahram Bodaghi
Summary: This study evaluated the LFP values in patients with JIA-associated uveitis and found that a decrease of LFP value >= 50% after 1 month of intensified treatment is a good early prognostic factor, indicating fewer ocular complications and better visual acuity.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2022)
Review
Medicine, General & Internal
William D. Renton, Jennifer Jung, Alan G. Palestine
Summary: The study evaluated the effectiveness and safety of tumor necrosis factor (TNF) inhibitors for the treatment of juvenile idiopathic arthritis associated uveitis (JIA-U) with 134 participants. The findings suggest that adalimumab appears to increase the likelihood of treatment success and decrease the likelihood of treatment failure when compared with placebo, while the evidence on etanercept is less conclusive. Further research is needed.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Article
Ophthalmology
Po-Yi Wu, Eugene Yu-Chuan Kang, Wei-Dar Chen, Wei-Yu Chiang, Cheng-Hsiu Wu, Chao-Yi Wu, Kuan-Jen Chen, Wei-Chi Wu, Hung-Da Chou, An-Ning Chao, Yih-Shiou Hwang
Summary: The aim of this study was to assess the epidemiology, treatment, and outcomes of juvenile idiopathic arthritis-associated uveitis in Taiwan. Among 722 JIA patients, 44 (6.1%) had uveitis. The mean ages of JIA and JIA-U diagnosis were 10.7 and 11.1 years, respectively. Male predominance and late age at JIA-U diagnosis were observed in Taiwan. Reactivation occurred in 25% of patients with inactivity lasting >= 6 months within 2 years.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2023)
Article
Ophthalmology
Achille Marino, Luca Marelli, Paolo Nucci, Roberto Caporali, Elisabetta Miserocchi
Summary: This study aimed to evaluate the efficacy and safety of subcutaneous tocilizumab in JIA patients with refractory uveitis. The results showed that SC-TCZ significantly reduced the rate of uveitis flare and achieved complete treatment response in some patients. Moreover, SC-TCZ was well-tolerated without any observed side effects.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2023)
Article
Ophthalmology
Justine R. Smith, Janet M. Matthews, Diana Conrad, Anthony J. Hall, Rachael L. Niederer, Davinder Singh-Grewal, Mei-Ling Tay-Kearney, Jane M. Wells, Sophia L. Zagora, Peter J. McCluskey
Summary: The Australian and New Zealand-based uveitis-specialized ophthalmologists have developed 18 consensus statements for managing chronic anterior uveitis in children with JIA, providing regionally applicable advice for ophthalmic care.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2021)
Article
Pharmacology & Pharmacy
Ryan Sol Funk, Mara L. Becker
Summary: Variability in methotrexate efficacy poses a challenge in treating juvenile idiopathic arthritis. This study aimed to explore the impact of methotrexate on plasma metabolome and identify metabolic biomarkers of efficacy in children with JIA. The research revealed diverse metabolic changes following methotrexate initiation, including metabolites associated with microbial metabolism and exogenous sources.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Immunology
Jie Zheng, Yong Wang, Jun Hu
Summary: This study explores the shared gene signatures and potential molecular mechanisms of polyarticular juvenile idiopathic arthritis (pJIA) and autoimmune uveitis (AU) through data analysis and functional enrichment analysis. Neutrophil degranulation may be considered a shared pathogenic mechanism, and the roles of ARID1A gene and hsa-miR-146a are worthy of further study. Additionally, periodic inspection of kidney function is also important.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Christoph Tappeiner, Han Sol Bae, Kai Rothaus, Karoline Walscheid, Arnd Heiligenhaus
Summary: The study aimed to analyze the occurrence and risk factors for macular edema (ME) in patients with juvenile idiopathic arthritis-associated uveitis (JIA-U). The results indicated that older age, worse eye conditions, and higher laser-flare photometry values were independent risk factors for ME manifestation.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Medicine, General & Internal
Weiyu Qi, Yu Xia, Xin Li, Jianzhong Cao
Summary: This study systematically evaluated and compared the efficacy and safety of methotrexate and leflunomide in the treatment of rheumatoid arthritis. The results indicate the need for more high-quality randomized controlled trials to further validate the effectiveness and safety of these drugs for patients.
Article
Pediatrics
Ashley M. Cooper, Elaine R. Flanagan, Tova Ronis, Baruch Goldberg, Ashley K. Sherman, Chelsey Smith, Gary N. Holland
Summary: The study found that there are different levels of knowledge regarding uveitis complications and recommended screening among patients with JIA and their parents. Regular discussions about the importance and risks of uveitis screening can lead to improved understanding of uveitis among patients and parents.
PEDIATRIC RHEUMATOLOGY
(2021)
Article
Rheumatology
Gregor Kuntze, Alberto Nettel-Aguirre, Julia Brooks, Shane Esau, Colleen Nesbitt, Dianne Mosher, Marinka Twilt, Susanne Benseler, Janet L. Ronsky, Carolyn A. Emery
Summary: This study examined the biomechanics of single leg squat (SLS) in youth with juvenile idiopathic arthritis (JIA) and their healthy peers. The results showed that JIA patients performed the SLS with more internally rotated hip, while female participants displayed better hip flexion/extension range of motion. Additionally, associations were found between body mass index, knee flexion angle, and hip range of motion during the SLS task.
ARTHRITIS CARE & RESEARCH
(2021)
Article
Rheumatology
Claire E. H. Barber, Diane Lacaille, Peter Faris, Dianne Mosher, Steven Katz, Jatin N. Patel, Sharon Zhang, Karen Yee, Cheryl Barnabe, Glen S. Hazlewood, Vivian Bykerk, Natalie J. Shiff, Marinka Twilt, Jennifer Burt, Susanne M. Benseler, Joanne Homik, Deborah A. Marshall
Summary: In Alberta, the proportion of RA patients seen by a rheumatologist within 1 year of diagnosis has increased, but the proportion of patients dispensed DMARD annually remains low. Although the median time to DMARD from first visit date has improved, a low percentage of patients receive treatment within the 14-day benchmark. The percentage of patients seen in annual follow-up varies between 73-80%.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Rheumatology
Melissa L. Mannion, Fenglong Xie, Daniel B. Horton, Sarah Ringold, Colleen K. Correll, Anne Dennos, Timothy Beukelman
Summary: Biologic medications have greatly improved disease control and outcomes for patients with juvenile idiopathic arthritis (JIA), but a substantial number of patients may require switching to a second biologic. The time to switch has decreased in recent years, and further studies are needed to evaluate outcomes and optimal timing of biologic switching.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Rheumatology
Kimberly A. Morishita, Linda Wagner-Weiner, Eric Y. Yen, Vidya Sivaraman, Karen E. James, Dana Gerstbacher, Ann M. Szymanski, Kathleen M. O'Neil, David A. Cabral
Summary: The study established standardized consensus treatment plans for severe pediatric AAV, providing the basis for evaluating pragmatic comparative effectiveness in a long-term registry in the future.
ARTHRITIS CARE & RESEARCH
(2022)
Article
Rheumatology
Michelle M. A. Kip, Sytze de Roock, Inge van den Berg, Gillian Currie, Deborah A. Marshall, Luiza R. Grazziotin, Marinka Twilt, Rae S. M. Yeung, Susanne M. Benseler, Sebastiaan J. Vastert, Nico Wulffraat, Joost F. Swart, Maarten J. IJzerman
Summary: This study quantifies the costs of hospital-associated care for juvenile idiopathic arthritis (JIA) and finds significant variations in costs among individuals and subtypes. Systemic JIA has the highest annual costs, primarily attributed to medication, and costs are highest in the first month after JIA diagnosis.
ARTHRITIS CARE & RESEARCH
(2022)
Article
Pediatrics
Liane D. Heale, Kristin M. Houghton, Elham Rezaei, Adam D. G. Baxter-Jones, Susan M. Tupper, Nazeem Muhajarine, Susanne M. Benseler, Gilles Boire, David A. Cabral, Sarah Campillo, Gaelle Chedeville, Anne-Laure Chetaille, Paul Dancey, Ciaran Duffy, Karen Watanabe Duffy, Janet Ellsworth, Jaime Guzman, Adam M. Huber, Roman Jurencak, Bianca Lang, Ronald M. Laxer, Kimberly Morishita, Kiem G. Oen, Ross E. Petty, Suzanne E. Ramsey, Johannes Roth, Rayfel Schneider, Rosie Scuccimarri, Lynn Spiegel, Elizabeth Stringer, Shirley M. L. Tse, Lori B. Tucker, Stuart E. Turvey, Rae S. M. Yeung, Alan M. Rosenberg
Summary: Children with newly diagnosed JIA in Canada have lower levels of physical activity compared to healthy children. The decline in physical activity levels over time is associated with disease activity and increased disease-specific psychosocial stress.
PEDIATRIC RHEUMATOLOGY
(2021)
Article
Pediatrics
Timothy Beukelman, Aimee Lougee, Roland A. Matsouaka, David Collier, Dax G. Rumsey, Jennifer Schenfeld, Scott Stryker, Marinka Twilt, Yukiko Kimura
Summary: This study characterizes contemporary patterns of ETN use in the CARRA Registry. Treatment was largely in keeping with American College of Rheumatology guidelines.
PEDIATRIC RHEUMATOLOGY
(2021)
Article
Rheumatology
Colleen Nesbitt, Gregor Kuntze, Clodagh Toomey, Shane Esau, Julia Brooks, Dianne Mosher, Marinka Twilt, Alberto Nettel-Aguirre, Luz Maria Palacios-Derflingher, Janet Ronsky, Susanne Benseler, Carolyn A. Emery
Summary: The study found that children and adolescents with JIA had lower levels of daily moderate-to-vigorous physical activity compared to their typically developing peers, highlighting the need for strategies to promote physical activity participation. Sex and age should be considered in research on the consequences of JIA.
RHEUMATOLOGY INTERNATIONAL
(2022)
Article
Rheumatology
Ruud H. J. Verstegen, Peter Shrader, Stephen J. Balevic, Timothy Beukelman, Colleen Correll, Anne Dennos, Thomas Phillips, Brian M. Feldman
Summary: This study aimed to determine the dose-response relationship of tumor necrosis factor (TNF) inhibition in the treatment of juvenile idiopathic arthritis (JIA). The results did not confirm the hypothesis that increased dosing of TNF inhibitors leads to improved treatment outcomes.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Pediatrics
Luiza R. Grazziotin, Gillian Currie, Marinka Twilt, Maarten J. Ijzerman, Michelle M. A. Kip, Hendrik Koffijberg, Susanne M. Benseler, Joost F. Swart, Sebastiaan J. Vastert, Nico M. Wulffraat, Rae S. M. Yeung, Deborah A. Marshall
Summary: This study evaluated prescription patterns of conventional and biologic disease modifying anti-rheumatic drugs (c-DMARDs and b-DMARDs) for children with juvenile idiopathic arthritis (JIA). The study found that within the first year of rheumatology care, 62% of patients were prescribed a c-DMARD and 21% were prescribed a b-DMARD. There were significant differences in prescription patterns among different subtypes of JIA, and many patients required multiple treatment lines.
PEDIATRIC RHEUMATOLOGY
(2022)
Article
Pediatrics
William Daniel Soulsby, Nayimisha Balmuri, Victoria Cooley, Linda M. Gerber, Erica Lawson, Susan Goodman, Karen Onel, Bella Mehta
Summary: Social determinants of health have a significant impact on the outcomes of rheumatoid arthritis treatment. Our study found that community poverty level, race/ethnicity, and economic factors are associated with disease activity and functional disability in polyarticular juvenile idiopathic arthritis patients.
PEDIATRIC RHEUMATOLOGY
(2022)
Article
Rheumatology
Jennifer J. Y. Lee, Simon W. M. Eng, Jaime Guzman, Ciaran M. Duffy, Lori B. Tucker, Kiem Oen, Rae S. M. Yeung, Brian M. Feldman
Summary: This study compared the ILAR and PRINTO JIA classification criteria in a cohort of JIA patients. The results showed that a large proportion of JIA patients were unclassifiable using the PRINTO criteria, and the alignment with clinicobiologic subtypes and adult forms of arthritis was not as good as the ILAR criteria.
ARTHRITIS & RHEUMATOLOGY
(2022)
Review
Economics
Gillian R. Currie, Brittany Gerber, Diane Lorenzetti, Karen MacDonald, Susanne M. Benseler, Francois P. Bernier, Kym M. Boycott, K. Vanessa Carias, Bettina Hamelin, Robin Z. Hayeems, Claire LeBlanc, Marinka Twilt, Gijs van Rooijen, Durhane Wong-Rieger, Rae S. M. Yeung, Deborah A. Marshall
Summary: Rare diseases impose a significant burden on various aspects. Limited evidence exists on the socioeconomic burden of rare diseases, particularly for those without available treatments. This study developed a framework to guide future research on the cost elements of rare diseases.
Article
Rheumatology
A. Chen, C. Mammen, J. Guzman, E. Al-Abadi, S. M. Benseler, R. A. Berard, D. Gerstbacher, M. Heshin-Bekenstein, S. Kim, M. Klein-Gitelman, P. P. Chavan, K. E. James, N. Martin, F. McErlane, C. Myrup, D. G. Noone, J. Raghuram, S. Shenoi, V Sivaraman, T. Tanner, R. S. M. Yeung, D. A. Cabral, K. A. Morishita
Summary: There is a lack of specific guidelines for optimal glucocorticoid dosing in pediatric ANCA-associated vasculitis (pAAV). This study found that lower glucocorticoid doses can reduce toxicity without reducing efficacy in pAAV-related renal disease. Higher glucocorticoid doses were associated with renal failure and plasmapheresis use, and adverse effects were high across all dosing groups. Glucocorticoid dosing did not associate with 12-month outcomes.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2022)
Article
Health Care Sciences & Services
Gillian R. Currie, Tram Pham, Marinka Twilt, Maarten J. IJzerman, Pauline M. Hull, Michelle M. A. Kip, Susanne M. Benseler, Glen S. Hazlewood, Rae S. M. Yeung, Nico M. Wulffraat, Joost F. Swart, Sebastian J. Vastert, Deborah A. Marshall
Summary: This study explores pediatric rheumatologists' approaches to treatment decision making for biologics in JIA, identifying attributes influencing initiation and tapering. Five pediatric rheumatologists participated in interviews, outlining varied tapering strategies. Fourteen attributes were selected for a BWS survey, covering patient characteristics and contextual factors. Additional research is needed to align these characteristics with patient and parent preferences.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH
(2022)
